Roche: FDA approves Tecentriq for liver cancer

(CercleFinance.com) - The US Food and Drug Administration has approved Roche's Tecentriq for the treatment of the most common form of liver cancer, the Swiss drugmaker said on Tuesday.


The FDA has approved Tecentriq in combination with Avastin, another Roche drug, for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

In a Phase III study, Tecentriq, in combination with Avastin, reduced the risk of death by 42% and reduced the risk of the disease worsening by 41%, compared with Bayer's sorafenib, Roche said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.